Skip to main content

Table 3 Univariate and multivariate regression analysis to identify predictors for hepatotoxicity related to erlotinib administration in lung cancer patients

From: Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

Characteristics

Unadjusted OR

(95% CI)

Model I

Model II

Adjusted OR (95% CI)

Attributable risk

Adjusted OR (95% CI)

Attributable risk

Male

0.598 (0.212–1.688)

0.251 (0.060–1.048)

 

0.266 (0.065–1.084)

 

Age ≥ 65

2.623 (0.902–7.633)

3.198 (1.023–9.997)*

68.7

3.540 (1.123–11.164)*

71.8

BSA ≥ 1.6

1.398 (0.460–4.244)

3.545 (0.787–15.972)

 

3.188 (0.723–14.053)

 

PPI

3.528 (0.984–12.651)

3.529 (0.916–13.595)

   

H2 blocker or PPI

3.083 (1.056–9.000)*

  

3.454 (1.114–10.713)*

71.0

  1. For model I construction, sex, age, BSA and PPI were included for analysis. For model II construction, sex, age, BSA and H2 blocker or PPI were included for analysis
  2. BSA body surface area, PPI proton pump inhibitor
  3. *P < 0.05